Breaking News Instant updates and real-time market news.

AMGN

Amgen

$236.90

-1.42 (-0.60%)

, GH

Guardant Health

$77.46

-0.96 (-1.22%)

16:23
01/13/20
01/13
16:23
01/13/20
16:23

Amgen announces strategic collaborations with Guardant, Qiagen

Amgen announced strategic collaborations with leading diagnostic companies Guardant Health (GH) and Qiagen (QGEN) to develop blood- and tissue-based companion diagnostics, or CDx, respectively, for investigational cancer treatment AMG 510. AMG 510 is the first KRASG12C inhibitor to advance to the clinic for investigation in treatment of multiple tumor types. KRAS G12C is one of the most frequently mutated oncogenes in human cancers. The agreements with both companies will initially focus on CDx tests for non-small cell lung cancer but allow for further development of the diagnostic tests for Amgen's other oncology clinical development programs.

AMGN

Amgen

$236.90

-1.42 (-0.60%)

GH

Guardant Health

$77.46

-0.96 (-1.22%)

QGEN

Qiagen

$35.13

0.545 (1.58%)

  • 13

    Jan

  • 30

    Jan

  • 05

    Feb

AMGN Amgen
$236.90

-1.42 (-0.60%)

01/03/20
HCWC
01/03/20
NO CHANGE
HCWC
Buy
Ligand royalties from Amgen may rise, but Novan hits bump, says H.C Wainwright
H.C. Wainwright analyst Joseph Pantginis noted that Ligand (LGND) partner Amgen (AMGN) announced the closing of its new 20.5% stake in BeiGene (BGNE) yesterday after the close, explaining that this could result in a likely bump up in Kyprolis royalty revenue as BeiGene is expected to commercialize Kyprolis in China over the next five to seven years. However, also after the close yesterday, another Ligand partner, Novan (NOVN), reported that the primary endpoint was missed in both studies testing SB206 in molloscum contagiosum patients. Until Novan gets FDA feedback about a potential path forward for SB206, he thinks investors will keep the program out of their estimates for Ligand's future revenue, said Pantginis. He maintains a Buy rating and $214 price target on Ligand shares.
12/24/19
12/24/19
NO CHANGE

Fly Intel: Top five analyst actions
Catch up on today's top five analyst actions with this list compiled by The Fly: 1. FedEx (FDX) downgraded to Hold from Buy at Argus with analyst John Eade saying while the stock has underperformed the market and its peer group he has "low confidence" that the company's earnings power can recover in the near term as its core FedEx Express revenues and margins are sliding. 2. AquaVenture (WAAS) was downgraded to Neutral from Buy at B. Riley FBR, to Hold from Buy at Lake Street, to Sector Perform from Outperform at RBC Capital, and to Market Perform from Outperform at Raymond James. The downgrades came after the company announced yesterday that it has agreed to be acquired by Culligan for $27.10 per share in cash. 3. MannKind (MNKD) initiated with an Outperform rating and $2.50 price target at Oppenheimer. 4. Amgen (AMGN) and Regeneron (REGN) were initiated with a Market Perform at Raymond James. 5. Stemline (STML) initiated with an Overweight rating at Cantor Fitzgerald. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/24/19
RAJA
12/24/19
INITIATION
RAJA
Market Perform
Raymond James sees Amgen valuation as 'fair,' starts at Market Perform
As previously reported, Raymond James analyst Dane Leone initiated coverage of Amgen with a Market Perform rating. He sees new potential growth areas, such as AMG 510, a first-in-class investigational KRAS G12C inhibitor, offsetting expected pressure on legacy branded drugs such as Enbrel, said Leone, who sees the stock's current valuation as "fair."
01/09/20
BMOC
01/09/20
NO CHANGE
Target $275
BMOC
Outperform
Amgen price target raised to $275 from $240 at BMO Capital
BMO Capital analyst Do Kim raised his price target for Amgen to $275 from $240 in order to include AMG 510 in his model with estimated peak sales of $2.4B in NSCLC and CRC only. Kim tells investors in a research note that he believes the Otezla acquisition will improve top-line growth to nearly 10% from flat previously, with potential for Otezla to exceed consensus estimates given Amgen's greater experience in the immunology space. The analyst made no change to his Outperform rating.
GH Guardant Health
$77.46

-0.96 (-1.22%)

01/06/20
SBSH
01/06/20
INITIATION
Target $100
SBSH
Buy
Guardant Health initiated with a Buy at Citi
Citi analyst Patrick Donnelly initiated coverage of Guardant Health with a Buy rating and $100 price target.
09/12/19
LEER
09/12/19
NO CHANGE
Target $130
LEER
Outperform
Guardant Health recent weakness a buying opportunity, says SVB Leerink
SVB Leerink analyst Puneet Souda views Guardant Health as a best-in-class liquid biopsy opportunity in a massive high growth market, with the company generating a conservative 60% revenue CAGR that is likely to accelerate as the overall LBx market grows. The analyst highlights buying opportunity amid recent weakness, and reiterates an Outperform rating and $130 price target on the shares given the catalyst path ahead over the next year.
11/08/19
ADAM
11/08/19
NO CHANGE
Target $125
ADAM
Buy
Guardant Health best-in-class growth play, says Canaccord
Canaccord analyst Mark Massaro called Guardant Health the best-in-class growth play in the Diagnostics space. The analayst called the huge Q3 beat "outstanding" as the company beat his model across the board, and raised guidance for 2019. He appreciates the company's near-term execution combined with its long-term strategic thinking and global vision, across cancers in late stage therapy selection, cancer monitoring, and early stage cancer screening. Massaro reiterated his buy rating and $125 price target on Guardant Health shares.
01/09/20
JPMS
01/09/20
NO CHANGE
JPMS
Danaher, Thermo named JPMorgan's top 2020 picks in Life Science Tools
JPMorgan analyst Tycho Peterson expects organic growth in the Life Science Tools & Diagnostics space to mirror 2019 against a "healthy backdrop" across biopharma and academic end markets. His top picks for 2020 are Danaher (DHR) and Thermo Fisher (TMO). The analyst also urges investors to take advantage of any downturn to add to "open-ended growth stories that trade at premium valuations," with Intuitive Surgical (ISRG) his top pick in this category. On the Smid-cap side, Peterson favors Guardant Health (GH), 10x Genomics (TXG) and NanoString (NSTG). For investors with a longer-term horizon, he recommend Adaptive Biotechnologies (ADPT). The analyst also continues to recommend Avantor (AVTR).
QGEN Qiagen
$35.13

0.545 (1.58%)

01/06/20
CCMC
01/06/20
DOWNGRADE
Target $35
CCMC
Hold
Qiagen downgraded to Hold from Buy at Commerzbank
Commerzbank analyst Daniel Wendorff downgraded Qiagen to Hold from Buy with a $35 price target.
01/07/20
WELS
01/07/20
INITIATION
Target $36
WELS
Equal Weight
Qiagen initiated with an Equal Weight at Wells Fargo
Wells Fargo analyst Dan Leonard initiated coverage of Qiagen with an Equal Weight rating and $36 price target.
01/06/20
SBSH
01/06/20
INITIATION
Target $35
SBSH
Neutral
Qiagen initiated with a Neutral at Citi
Citi analyst Patrick Donnelly initiated coverage of Qiagen with a Neutral rating and $35 price target.
12/26/19
BREN
12/26/19
NO CHANGE
BREN
Buy
Qiagen suitors remain interested, new talks still possible, says Berenberg
Berenberg analyst Scott Bardo said his talks with Qiagen showed that "price was not the biggest impediment" to getting a deal done and he believes suitors may still be interested in the company despite its decision in the near-term to go it alone. Bardo, who would not rule out the company renewing deal talks at "some point in the future," keeps a Buy rating on shares of Qiagen, which are down $8.27, or 20%, to $33.20 in afternoon trading following the company's announcement on Tuesday that it had ended its exploration of strategic alternatives without making a deal.

TODAY'S FREE FLY STORIES

TLGT

Teligent

$0.40

-0.0025 (-0.62%)

15:53
01/18/20
01/18
15:53
01/18/20
15:53
Conference/Events
Teligent to hold a special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

AYTU

Aytu BioScience

$0.80

0.0014 (0.18%)

15:48
01/18/20
01/18
15:48
01/18/20
15:48
Conference/Events
Aytu BioScience to hold a special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

DVA

DaVita

$79.45

0.43 (0.54%)

15:32
01/18/20
01/18
15:32
01/18/20
15:32
Conference/Events
DaVita to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

TSM

TSMC

$58.58

-0.18 (-0.31%)

09:16
01/18/20
01/18
09:16
01/18/20
09:16
Periodicals
Taiwan tech stocks can ignore China's bluster for now, Barron's says »

China's government…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KKR

KKR

$31.20

0.7 (2.30%)

, APO

Apollo Global

$50.35

1.26 (2.57%)

09:03
01/18/20
01/18
09:03
01/18/20
09:03
Periodicals
KKR undervalued compared with peers, Barron's says »

KKR (KKR) gained 50% last…

KKR

KKR

$31.20

0.7 (2.30%)

APO

Apollo Global

$50.35

1.26 (2.57%)

ARES

Ares Management

$37.29

0.47 (1.28%)

BX

Blackstone

$60.79

0.62 (1.03%)

CG

Carlyle Group

$33.30

0.36 (1.09%)

HLNE

Hamilton Lane

$67.25

-0.02 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 30

    Jan

  • 31

    Jan

  • 31

    Jan

  • 04

    Feb

  • 04

    Feb

  • 05

    Feb

  • 13

    Feb

  • 17

    Feb

  • 26

    Feb

SPCE

Virgin Galactic

$15.65

0.685 (4.58%)

, TWNK

Hostess Brands

$14.03

0.02 (0.14%)

08:56
01/18/20
01/18
08:56
01/18/20
08:56
Periodicals
'Blank-check' companies hot on Wall Street, Barron's says »

More than a quarter of…

SPCE

Virgin Galactic

$15.65

0.685 (4.58%)

TWNK

Hostess Brands

$14.03

0.02 (0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 04

    Mar

GOOG

Alphabet

$1,480.28

28.34 (1.95%)

, NFLX

Netflix

$339.56

0.89 (0.26%)

08:47
01/18/20
01/18
08:47
01/18/20
08:47
Periodicals
Peacock's pricing might be 'killer feature,' Barron's says »

This week, Peacock…

GOOG

Alphabet

$1,480.28

28.34 (1.95%)

NFLX

Netflix

$339.56

0.89 (0.26%)

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$47.48

0.62 (1.32%)

GOOGL

Alphabet Class A

$1,479.12

29.29 (2.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 22

    Jan

  • 23

    Jan

  • 03

    Feb

  • 03

    Feb

  • 10

    Feb

JWN

Nordstrom

$40.34

-0.15 (-0.37%)

, WMT

Walmart

$114.93

-0.96 (-0.83%)

08:36
01/18/20
01/18
08:36
01/18/20
08:36
Periodicals
Casper IPO highlights tech's promise, troubles, Barron' says »

Mattresses have been…

JWN

Nordstrom

$40.34

-0.15 (-0.37%)

WMT

Walmart

$114.93

-0.96 (-0.83%)

CSPR

Casper Sleep

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 18

    Feb

BA

Boeing

$324.11

-7.89 (-2.38%)

, DDAIF

Daimler AG

$0.00

(0.00%)

08:12
01/18/20
01/18
08:12
01/18/20
08:12
On The Fly
Week in Review: How Trump's policies moved stocks »

Catch up on the top…

BA

Boeing

$324.11

-7.89 (-2.38%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$13.76

-0.14 (-1.01%)

VWAGY

Volkswagen

$0.00

(0.00%)

FSLR

First Solar

$53.51

-0.42 (-0.78%)

AAPL

Apple

$318.66

3.33 (1.06%)

DQ

Daqo New Energy

$53.61

-0.025 (-0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 29

    Jan

SPOT

Spotify

$148.20

-3.59 (-2.37%)

18:15
01/17/20
01/17
18:15
01/17/20
18:15
Periodicals
Spotify in talks to acquire The Ringer, WSJ reports »

Spotify is in discussions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

CE

Celanese

$117.54

-0.53 (-0.45%)

18:00
01/17/20
01/17
18:00
01/17/20
18:00
Hot Stocks
Celanese announces acetyl intermediates price increases »

Celanese Corporation will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

BYND

Beyond Meat

$109.20

-1.16 (-1.05%)

17:58
01/17/20
01/17
17:58
01/17/20
17:58
Periodicals
Beyond Meat rival gets green light in Canada, The Star says »

Impossible Foods, a maker…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DBD

Diebold

$11.09

-0.49 (-4.23%)

17:42
01/17/20
01/17
17:42
01/17/20
17:42
Periodicals
Breaking Periodicals news story on Diebold »

Diebold Nixdorf divests…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEF

iShares 7-10 Year Treasury Bond ETF

$111.28

-0.13 (-0.12%)

, SHY

iShares 1-3 Year Treasury Bond

$84.73

-0.005 (-0.01%)

17:32
01/17/20
01/17
17:32
01/17/20
17:32
General news
Weekly CFTC Commitment of Traders highlights »

2-YEAR U.S. TREASURY net…

IEF

iShares 7-10 Year Treasury Bond ETF

$111.28

-0.13 (-0.12%)

SHY

iShares 1-3 Year Treasury Bond

$84.73

-0.005 (-0.01%)

SPY

SPDR S&P 500 ETF Trust

$331.98

1.08 (0.33%)

SLV

iShares Silver Trust

$16.82

0.04 (0.24%)

GLD

SPDR Gold Shares

$146.59

0.29 (0.20%)

FXE

Euro Currency Trust

$105.10

-0.43 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBSFY

Ubisoft

$0.00

(0.00%)

17:32
01/17/20
01/17
17:32
01/17/20
17:32
Periodicals
Ubisoft to restructure editorial team after difficult 2019, VGC reports »

Ubisoft intends to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 18

    Feb

IMVT

Immunovant

$17.04

-0.01 (-0.06%)

17:27
01/17/20
01/17
17:27
01/17/20
17:27
Syndicate
Breaking Syndicate news story on Immunovant »

Immunovant files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TBLT

ToughBuilt

$0.33

-0.0255 (-7.11%)

17:20
01/17/20
01/17
17:20
01/17/20
17:20
Syndicate
ToughBuilt files to sell common stock, no amount given »

Maxim acted as sole book…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYO

Myomo

$0.32

0.0062 (1.98%)

17:18
01/17/20
01/17
17:18
01/17/20
17:18
Conference/Events
Myomo to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

SRRA

Sierra Oncology

$0.40

-0.02 (-4.76%)

17:14
01/17/20
01/17
17:14
01/17/20
17:14
Conference/Events
Sierra Oncology to host virtual special shareholder meeting »

Virtual Special…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

SRNE

Sorrento Therapeutics

$4.26

-0.15 (-3.40%)

17:10
01/17/20
01/17
17:10
01/17/20
17:10
Syndicate
Breaking Syndicate news story on Sorrento Therapeutics »

Sorrento Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKER

Akers Biosciences

$3.45

-0.1 (-2.82%)

17:01
01/17/20
01/17
17:01
01/17/20
17:01
Hot Stocks
Akers Biosciences reaches settlement agreements on two derivative actions »

Akers Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECA

Encana

$4.09

-0.18 (-4.22%)

16:40
01/17/20
01/17
16:40
01/17/20
16:40
Hot Stocks
Encana receives court approval for reorganization »

Encana Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

MBRX

Moleculin Biotech

$0.96

0.0122 (1.29%)

16:38
01/17/20
01/17
16:38
01/17/20
16:38
Syndicate
Breaking Syndicate news story on Moleculin Biotech »

Moleculin Biotech files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VOD

Vodafone

$20.07

-0.225 (-1.11%)

, BT

BT Group

$0.00

(0.00%)

16:37
01/17/20
01/17
16:37
01/17/20
16:37
Periodicals
BT, Vodafone consider urging PM Johnson not to ban Huawei in U.K., Reuters says »

BT Group (BT) and…

VOD

Vodafone

$20.07

-0.225 (-1.11%)

BT

BT Group

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
01/17/20
01/17
16:30
01/17/20
16:30
Options
Preliminary option volume of 28.7M today »

Preliminary option volume…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.